Earnings Feed
Start Free
Neurogene Inc.·4

Jul 2, 6:42 PM ET

Cvijic Christine Mikail 4

Research Summary

AI-generated summary

Updated

Neurogene (NGNE) President/CFO Christine Cvijic Sells Shares

What Happened
Christine Cvijic, President, Chief Financial Officer and a director of Neurogene Inc. (NGNE), sold a total of 4,800 shares in open-market transactions on July 1–2, 2026. The sales consisted of 739 shares at a weighted-average price of $34.06 ($25,170), 2,531 shares at $34.58 ($87,519), and 1,530 shares at $35.23 ($53,897), for aggregate proceeds of approximately $166,586. These were sales (not purchases) and therefore are generally routine dispositions rather than purchases signaling added insider conviction.

Key Details

  • Transaction dates and reported amounts:
    • 2026-07-01: 739 shares @ $34.06 — $25,170 (weighted avg; prices ranged $34.005–$34.095).
    • 2026-07-02: 2,531 shares @ $34.58 — $87,519 (weighted avg; prices ranged $34.05–$34.99).
    • 2026-07-02: 1,530 shares @ $35.23 — $53,897 (weighted avg; prices ranged $35.11–$35.255).
  • Total sold: 4,800 shares for about $166,586.
  • Shares held after the sales: 4,800 shares held jointly by Ms. Cvijic and her spouse (per filing).
  • Notable footnotes:
    • Transactions were executed pursuant to a 10b5-1 trading plan adopted August 18, 2025; sold shares were held jointly with spouse David Cvijic.
    • Prices reported are weighted averages; the filer has offered to provide a breakdown of quantities at each individual price within the disclosed ranges upon request.
    • The filing discloses outstanding restricted stock units: 10,635 (vest Mar 13, 2027), 13,533 (vest in installments Mar 26, 2027 & Mar 26, 2028), and 22,000 (vest in installments Feb 20, 2027–2029).
  • Timeliness: Form 4 was filed on July 2, 2026 covering trades on July 1–2, 2026 (filed within the usual Form 4 reporting window).

Context
These were planned dispositions under a pre-established 10b5-1 plan (a common mechanism executives use to sell shares on a set schedule). Sales do not necessarily indicate a change in view about the company; purchases typically carry more informational weight. The filing is informational—retail investors may consider this alongside company fundamentals and broader insider activity.